Your AI-Trained Oncology Knowledge Connection!
Daniel J. George, MD, is the Eleanor Easley Distinguished Professor, a professor of medicine, a professor in urology, and a professor in surgery at the Duke University School of Medicine and a member of the Duke Cancer Institute.
Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses the results of the prospective multicenter Abi Race trial, which compared outcomes of African-American and Caucasian patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (Zytiga) and prednisone.
Daniel J. George, MD, director, GU Oncology, Duke Cancer Institute, discusses the use of sunitinib to treat patients with renal cell carcinoma (RCC).
Daniel J. George, MD, Director, GU Oncology, Duke Cancer Institute, discusses critical phase III clinical trials in metastatic renal cell carcinoma.
Daniel J. George, MD, from the Duke Cancer Institute, discusses the potential to incorporate radium-223 into combination strategies to treat patients with metastatic castation-resistant prostate cancer.
Daniel J. George, MD, from the Duke Cancer Institute, elaborates on the incorporation of radium-223 into the treatment of patients with metastatic castration-resistant prostate cancer.
